AT-02 antibody-peptide fusion protein acts as pan-amyloid opsonin, enhancing phagocytosis and complement fixation

Systemic amyloidosis involves progressive accumulation of diverse amyloid fibrils and extracellular matrix components, leading to severe organ dysfunction and often fatal outcomes. Currently, over twenty different proteins form systemic amyloid fibrils, making targeted therapy complex as it often requires individualized approaches. For example, treatments for AL amyloidosis primarily focus on anti-plasma cell regimens, not direct amyloid removal. There is a critical need for universal strategies to eliminate tissue amyloid deposits, which could significantly improve organ function and patient prognosis by directly clearing these pathological aggregates.

Researchers developed AT-02 (zamubafusp alfa), an immunoglobulin-peptide fusion protein consisting of a humanized IgG1 antibody fused to a pan-amyloid reactive peptide, p5R. The study aimed to characterize AT-02's ability to bind amyloid and act as an opsonin. They investigated its specific reactivity with various amyloid types and demonstrated its functional capacity to enhance phagocytosis of amyloid extracts. Additionally, the team assessed AT-02's ability to induce complement fixation, a key immune clearance mechanism, in in vitro or ex vivo assays using amyloid material. No specific animal models, cell lines, or quantitative doses were detailed in the abstract.

AT-02 (zamubafusp alfa) demonstrated specific reactivity with a broad spectrum of amyloid types, attributed to its binding to two ubiquitous components of all amyloids: the amyloid fibrils themselves and highly sulfated heparan sulfate glycans. This pan-amyloid binding capability is crucial, as it potentially obviates the need for developing individualized immunoglobulins for each amyloidosis type. The core functional finding highlights AT-02's role as an effective opsonin for amyloid. This was evidenced by its ability to significantly enhance the cellular process of phagocytosis when applied to amyloid extracts. Furthermore, AT-02 was shown to induce complement fixation, a critical immune response pathway that tags pathogens and cellular debris for clearance. These findings collectively suggest a dual mechanism of action for AT-02 in promoting amyloid removal. While the abstract describes these effects qualitatively, specific quantitative data, such as percent enhancement of phagocytosis or fold-change in complement activation, were not provided. > AT-02 effectively functions as an opsonin, enhancing phagocytosis of amyloid extracts and inducing complement fixation, indicating a broad amyloid clearance mechanism.